olivLaw · US equity research
Bioceres Crop Solutions Corp. BIOX
Agricultural Chemicals · SIC 2870 · Vertical: Agricultural Chemicals (SIC 2870)
Bioceres Crop Solutions develops and commercializes biotechnology-based crop productivity solutions, from seeds and microbial inoculants to biological and next-generation nutrition and protection products. In fiscal 2025 the company reported revenues of 335.1 million USD, down from 464.8 million USD a year earlier, amid significant pressure on its debt.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Bioceres Crop Solutions Corp. (BIOX) stock was 0.25 USD (+12.12% on the day), with market capitalisation 16.2 m USD, dividend yield 0.45%, beta 1.23, 52-week range 0.20–1.93 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 43.8
- weak (30–45)
- Bollinger (20, 2)
- 0.18 – 0.34
- in the lower half of the band · %B 0.44 · band width 61.4%
- SMA 50 / 200
- 0.34 / 0.45
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.03 / -0.03
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −26.8% | −1.1% | −25.7 pp | — |
| 3 months | −30.4% | −0.5% | −29.9 pp | — |
| 6 months | −47.4% | +4.4% | −51.8 pp | — |
| Year to date | −80.7% | +12.3% | −93.0 pp | — |
| 1 year | −85.7% | +13.5% | −99.2 pp | −10.3% |
| 3 years | −97.6% | +76.4% | −174.0 pp | −24.4% |
| 5 years | −98.0% | +63.7% | −161.7 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | ⚠ 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 133.5 m | 160.6 m | 173.1 m | 209.5 m | 334.8 m | 420.1 m | 464.8 m | 335.1 m |
| Revenue YoY | unavailable | +20.3% | +7.8% | +21.0% | — | +25.4% | +10.6% | −27.9% |
| Net income | -11.0 m | -18.4 m | 3.4 m | -6.9 m | -7.2 m | 18.8 m | 4.3 m | -55.4 m |
| Net income YoY | unavailable | unavailable | unavailable | −304.5% | — | unavailable | −77.2% | −1,396.1% |
| Diluted EPS | -0.39 | -0.60 | 0.09 | -0.18 | -0.17 | 0.30 | 0.07 | -0.88 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | −290.0% | — | unavailable | −77.4% | −1,402.2% |
| net % | -8.3% | -11.4% | 1.9% | -3.3% | -2.2% | 4.5% | 0.9% | -16.5% |
| Free cash flow | 15.6 m | 27.7 m | 7.7 m | -9.0 m | -21.0 m | -8.8 m | 31.9 m | 44.3 m |
The series breaks before 2022: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Jun 2025
- Cash
- 32.7 m USD
- Financial debt
- 157.9 m USD
- Net debt
- 125.2 m USD
- Equity
- 295.2 m USD
- Total assets
- 763.6 m USD
- Debt / equity
- 0.53x
- Current ratio
- 0.91x
- ROE
- -17.1%
- ROA
- -6.9%
- FCF margin
- 13.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 173.1 m | 209.5 m | 334.8 m | 420.1 m | 464.8 m | 335.1 m | SEC (XBRL)· 10 Nov 2025verified |
| Cost of revenue | 93.6 m | 118.6 m | 208.4 m | 235.5 m | 278.2 m | 203.4 m | SEC (XBRL)· 10 Nov 2025verified |
| Gross profit | 79.5 m | 90.9 m | 126.5 m | 184.6 m | 186.6 m | 131.7 m | SEC (XBRL)· 10 Nov 2025verified |
| Research & development | 4.2 m | 5.6 m | 6.9 m | 15.3 m | 17.2 m | 14.9 m | SEC (XBRL)· 10 Nov 2025verified |
| Operating income | 39.1 m | 38.4 m | 39.9 m | 54.2 m | 45.9 m | -2.2 m | SEC (XBRL)· 10 Nov 2025verified |
| Interest expense | 20.9 m | 21.2 m | 17.9 m | 23.8 m | 26.9 m | 28.8 m | SEC (XBRL)· 10 Nov 2025verified |
| Pre-tax income | 6.4 m | 10.5 m | 14.1 m | 19.1 m | 11.1 m | -57.6 m | SEC (XBRL)· 10 Nov 2025verified |
| Income tax | 2.2 m | 14.4 m | 18.0 m | -1.1 m | 3.8 m | 1.3 m | SEC (XBRL)· 10 Nov 2025verified |
| Net income | 3.4 m | -6.9 m | -7.2 m | 18.8 m | 4.3 m | -55.4 m | SEC (XBRL)· 10 Nov 2025verified |
| Diluted EPS | 0.09 | -0.18 | -0.17 | 0.30 | 0.07 | -0.88 | SEC (XBRL)· 10 Nov 2025verified |
| Weighted average diluted shares | 36.4 m | 39.2 m | 42.3 m | 63.2 m | 63.5 m | 63.2 m | SEC (XBRL)· 10 Nov 2025verified |
| Dividend per share | — | — | — | 0.01 | 0.00 | 0.00 | SEC (XBRL)· 10 Nov 2025derived |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 42.5 m | 36.0 m | 33.5 m | 48.1 m | 44.5 m | 32.7 m | SEC (XBRL)· 10 Nov 2025verified |
| Receivables | 73.5 m | 88.8 m | 111.8 m | 158.0 m | 207.3 m | — | SEC (XBRL)· 30 Oct 2024verified |
| Inventories | 29.3 m | 61.0 m | 126.0 m | 140.4 m | 125.9 m | 87.6 m | SEC (XBRL)· 10 Nov 2025verified |
| Current assets | 164.7 m | 211.5 m | 297.7 m | 397.1 m | 408.7 m | 308.3 m | SEC (XBRL)· 10 Nov 2025verified |
| Property, plant & equipment, net | 41.5 m | 48.0 m | 49.9 m | 67.9 m | 74.6 m | 74.6 m | SEC (XBRL)· 10 Nov 2025verified |
| Goodwill | 25.5 m | 28.8 m | 36.1 m | 112.2 m | 112.2 m | 112.2 m | SEC (XBRL)· 10 Nov 2025verified |
| Intangibles (excl. goodwill) | 35.3 m | 67.3 m | 76.7 m | 173.8 m | 176.9 m | 181.2 m | SEC (XBRL)· 10 Nov 2025verified |
| Total assets | 297.6 m | 394.6 m | 518.2 m | 818.1 m | 852.5 m | 763.6 m | SEC (XBRL)· 10 Nov 2025verified |
| Accounts payable | 57.3 m | 72.1 m | 125.8 m | 150.8 m | 168.7 m | 96.4 m | SEC (XBRL)· 10 Nov 2025verified |
| Short-term debt | 63.7 m | 76.8 m | 71.3 m | 107.6 m | 136.7 m | 119.7 m | SEC (XBRL)· 10 Nov 2025verified |
| Long-term debt | 41.2 m | 48.0 m | 74.2 m | 60.7 m | 42.1 m | 38.2 m | SEC (XBRL)· 10 Nov 2025verified |
| Current liabilities | 130.6 m | 168.0 m | 222.7 m | 298.7 m | 329.3 m | 338.0 m | SEC (XBRL)· 10 Nov 2025verified |
| Total liabilities | 236.8 m | 304.3 m | 359.9 m | 487.6 m | 501.2 m | 468.4 m | SEC (XBRL)· 10 Nov 2025verified |
| Equity | 60.7 m | 90.3 m | 158.3 m | 330.5 m | 351.4 m | 295.2 m | SEC (XBRL)· 10 Nov 2025verified |
| Shares outstanding at year end | 0 | 41.1 m | 45.9 m | 62.8 m | 62.8 m | 63.2 m | SEC (XBRL)· 10 Nov 2025verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 9.3 m | -6.2 m | -17.5 m | 2.6 m | 41.7 m | 49.9 m | SEC (XBRL)· 10 Nov 2025verified |
| Capex | 1.6 m | 2.8 m | 3.5 m | 11.4 m | 9.8 m | 5.6 m | SEC (XBRL)· 10 Nov 2025verified |
| Free cash flow | 7.7 m ≈ | -9.0 m ≈ | -21.0 m ≈ | -8.8 m ≈ | 31.9 m ≈ | 44.3 m ≈ | SEC (XBRL)· 10 Nov 2025derived |
| Investing cash flow | -7.8 m | -8.3 m | 2.9 m | -25.7 m | -28.7 m | -6.1 m | SEC (XBRL)· 10 Nov 2025verified |
| Financing cash flow | 33.5 m | 7.4 m | 14.8 m | 33.0 m | -10.1 m | -50.7 m | SEC (XBRL)· 10 Nov 2025verified |
| Dividends paid | — | — | — | 452.1 k | 174.8 k | 72.1 k | SEC (XBRL)· 10 Nov 2025verified |
| Share repurchases | 30.9 k | 3.5 m | — | 3.0 m | 734.4 k | 926.9 k | SEC (XBRL)· 10 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- score weight coverage: 54.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 16.2 m USD
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
54% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.01 – 68.85 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)21.85 – 68.85 (Mid 33.36)WACC 5.4% · starting FCFF 68.5 m USD · terminal value share of EV 87%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)0.01 – 0.02 (Mid 0.02)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 54.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -0.4% | 40 (vs peers) | 19% |
| Net margin · Quality | -16.5% | 30 (vs peers) | 12% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 0.0% | 0 (on a fixed band) | 15% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -0.1x | 0 (on a fixed band) | 12% |
| Current ratio · Balance sheet | 0.9x | 9 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 273.7% | 100 (on a fixed band) | 15% |
| Shareholder yield (distributions) · Returns | 6.2% | 88 (on a fixed band) | 12% |
| Payout ratio (FCF) · Returns | 0.2% | 100 (on a fixed band) | 8% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet4/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality36/100 · 2/3 factors with a value
- Returns93/100 · 2/2 factors with a value
- Valuation· partial100/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Bioceres Crop Solutions Corp. (BIOX). Latest full fiscal year: 2025; data up to 2025-06-30.
Figures computed from the financial statements: revenue 335.1 m USD in 2025; YoY growth -27.9%; net margin -16.5%; ROE -19.1%.
The estimated value range is 10.93–34.44 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 16.69 USD, the price of 0.25 USD leaves a potential of 6,484.9% (value / price − 1) and a margin of safety of 98.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 54.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF yield: 273.7%
- Shareholder yield (distributions): 6.2%
- Payout ratio (FCF): 0.2%
- The price is below the estimated value range
What contradicts it
- Net margin: -16.5%
- Revenue CAGR 3Y: 0.0%
- Interest coverage: -0.1x
- Current ratio: 0.9x
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA.
Versus the vertical median
Agricultural Chemicals (SIC 2870) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRNutrien Ltd. | 41.0 bn | 15.5 | 9.1% | 8.4% | +3.5% | +24% / +35% |
| CFCf Industries Holdings, Inc. | 16.9 bn | 7.9 | 46.7% | 32.3% | +19.3% | +42% / +49% |
| MOSMosaic Co | 6.9 bn | — | -9.3% | -9.4% | +8.4% | −12% / −40% |
| ICLIcl Group Ltd. | 5.9 bn | 25.4 | 3.9% | 3.2% | +4.6% | −18% / −9% |
| SMGScotts Miracle-Gro Co | 3.9 bn | 55.8 | — | 2.1% | −3.9% | +19% / +21% |
| UANCvr Partners, LP | 1.2 bn | 11.1 | — | 16.1% | +15.4% | +16% / +64% |
| AVDAmerican Vanguard Corporation | 28.8 m | — | -26.5% | -10.7% | −5.9% | −79% / −90% |
| BIOXBioceres Crop Solutions Corp. | 16.2 m | — | -19.1% | -16.5% | −27.9% | −86% / −98% |
| SNESSenestech, Inc. | 6.6 m | — | -107.4% | -294.7% | +19.6% | −58% / −87% |
| CBUSCibus, Inc. | 6.2 m | — | -225.9% | -2,258.9% | −14.6% | −9% / −90% |
| EVGNEvogene Ltd. | 3.1 m | 0.3 | — | -220.2% | −30.9% | −66% / −95% |
1- and 3-year price returns: for BIOX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 10 Nov 2025; since then the company filed 20-F (30 Oct 2026), 6-K (21 Sept 2026), 6-K (16 Sept 2026), 6-K (22 Jun 2026), 6-K (01 Jun 2026), 6-K (12 May 2026).
In brief
Bioceres Crop Solutions develops and commercializes biotechnology-based crop productivity solutions, from seeds and microbial inoculants to biological and next-generation nutrition and protection products. In fiscal 2025 the company reported revenues of 335.1 million USD 1, down from 464.8 million USD a year earlier 1, amid significant pressure on its debt.
SWOT
Strengths
- The company has a broad portfolio of patents, brands and biological products built on an integrated technology platform 1.
- Relationships with farmers and distributors provide a commercial channel and rapid market access for new products 1.
- The collaboration and joint venture model reduces capital exposure in developing new technologies 1.
Weaknesses
Opportunities
- Expanding the HB4 licensing model could generate revenue without the direct costs of selling seeds 1.
- Demand for biological solutions with lower environmental impact could support growth of the portfolio 1.
- Partnerships with global distributors could facilitate entry into new markets, including Europe 1.
Threats
- Economic and political instability in Argentina and other Latin American countries could affect operations and results 1.
- Changes in export duty rules, currency controls or patent regimes could affect costs and revenues 1.
- If debt obligations cannot be met, lenders could accelerate repayment and enforce their security interests 1.
Risks
- Covenant breaches and debt reclassificationhigh
The company reported breaches of certain financial covenants, and part of its notes was reclassified as a current liability 1. Future breaches could lead to accelerated repayment 1.
- Liquidity and need for additional capitalhigh
The company states it will need additional capital, and access to financing on acceptable terms is not assured 1.
- Dependence on the licensed HB4 technologymedium
The seed business depends on a licensed technology that is subject to termination provisions, and the shift from direct sales to licensing is a complex process 1.
- Exposure to Latin Americahigh
Macroeconomic, currency and fiscal risks in Argentina and Brazil could affect revenues and margins 1.
- Weather and seasonalitymedium
Unusual weather conditions could delay orders and change quarterly results 1.
Investment thesis
What would need to be true (bull case)
- If the shift to licensing reduces fixed costs, the company could improve margins and achieve a more predictable revenue stream 1.
- A large portfolio of patents, brands and biological products could support a competitive position in regenerative agriculture 1.
- Partnerships with global players such as Syngenta could bring payments and co-funding for research, easing capital pressure 1.
What would break the thesis
- The net loss and negative operating result in fiscal 2025 could indicate difficulty converting revenue into profit 1.
- High-interest debt and covenant breaches could limit financial flexibility and could force asset sales 1.
- Exposure to volatile Latin American economies could continue to weigh on demand and customers' ability to pay 1.
What to watch
- Revenue from HB4 licensing and the Syngenta agreements2027
- Seasonal quarterly results and the evolution of Adjusted EBITDAQ1 2027
- Convertible notes and cash interest payments2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 10 Nov 2025; since then the company filed 20-F (30 Oct 2026), 6-K (21 Sept 2026), 6-K (16 Sept 2026), 6-K (22 Jun 2026), 6-K (01 Jun 2026), 6-K (12 May 2026).
The business
Bioceres Crop Solutions Corp. is a Cayman Islands company with principal executive offices in Rosario, Argentina, which presents itself as a leader in developing and commercializing productivity solutions designed to regenerate agricultural ecosystems and make crops more resilient to climate change 1. Its portfolio includes more than 1,600 brands and more than 650 registered products, and its inputs are marketed in more than 45 countries, mainly in South America, the United States and Europe 1. The business model relies on partnerships, joint ventures and acquisitions, which reduce capital exposure in technology development 1. In fiscal 2025 the company moved its HB4 technology to a licensing model, ending direct branded seed sales 1.
Activity is highly seasonal, with sales concentrated in the third and fourth calendar quarters, aligned with the South American summer planting season and the Northern Hemisphere summer season 1. The company also describes exposure to agricultural commodity prices, weather conditions and macroeconomic volatility in Latin America, including Argentina, where hyperinflation accounting applied until July 2022 1. The financing structure includes convertible and non-convertible notes with high interest rates, part of which is paid in kind 1.
Segments
Biological crop nutrition and protection
This line includes seed inoculants, biofertilizers, biostimulants and a full range of biocontrol products such as bionematicides, biofungicides and bioinsecticides 1. The exclusive global distribution agreement with Syngenta for Rizobacter seed treatment solutions is an important reference point 1.
Seed and genetic technologies
The company offers seed germplasm, GMO and non-GMO traits and ready-to-use seed pack solutions 1. In fiscal 2025 the seed business was restructured, with the HB4 technology now licensed to breeding organizations such as Grupo Don Mario and the Colorado Wheat Research Foundation 1.
Market context
The company describes the biological agriculture market as a dynamic segment of agriculture focused on reducing agriculture's impact on climate change and biodiversity loss 1. Demand depends on agricultural commodity prices, input costs, weather conditions and farmers' planting decisions 1.
The market is strongly influenced by the economies of Latin America, where the company earns a significant part of its revenue, and by fiscal and currency conditions in Argentina and Brazil 1. Changes in export duties and import controls have altered access to the FX market and operating costs 1.
Trends
- Biology as a response to climate changetailwind
Agricultural companies increasingly seek solutions that lower environmental impact, and biological technologies fit this demand 1. This trend could support adoption of the company's products if farmers change their practices 1.
- Agricultural policy adjustments in Argentinamixed
Temporary and then permanent cuts to agricultural export duties, and the elimination of the blend dollar in April 2025, changed the conditions under which export proceeds are settled 1. The effect differs depending on the structure of receipts 1.
- Pressure from the cost of debtheadwind
High interest rates and partial payment of interest in kind could increase the balance due at maturity, which could limit financial flexibility 1. The company reported breaches of certain financial covenants 1.
- Regulation and access to new productsmixed
Regulatory approvals for products under development can be slow and costly, and delays may affect sales in certain jurisdictions 1. The partnership-based model reduces part of this pressure 1.
Competitive position
The company states it faces intense competition in crop productivity products, which requires continuous technological development 1. Competition is present in seeds, biologicals and crop protection alike 1.
Advantages cited by the company include brands recognized by farmers, access to farmers through its historical shareholders and distribution partnerships with global players such as Syngenta and Corteva 1. Patent protection is considered a competitive advantage but remains exposed to legal and technological challenges 1.
- Syngenta
Global exclusive distribution partner for Rizobacter seed treatment products, also referenced as a player in biologicals and seed treatment.
- Corteva AgriscienceCTVA
European partner for a bioinsecticide and distributor of seed-applied technologies, which can also compete in the same product categories.
- Grupo Don Mario
Soybean breeder that obtained rights to use the Verdeca platform, acting as both a partner and a player in the seed market.
- Colorado Wheat Research Foundation
Organization managing access to the HB4 wheat trait in the United States and able to influence distribution in that segment.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Bioceres (BIOX) Q4 2026 Earnings Call TranscriptYahoo Finance — News · 15 Sept 2026 · EN
- Bioceres Crop Solutions Corp. Q4 2026 Earnings Call SummaryYahoo Finance — News · 15 Sept 2026 · EN
The latest news item in our archive is from 15 Sept 2026; the newest SEC filing is from 30 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Annual report (foreign issuer)30 Oct 2026
- Current report (foreign issuer)21 Sept 2026
- Current report (foreign issuer)16 Sept 2026
- Current report (foreign issuer)22 Jun 2026
- Current report (foreign issuer)01 Jun 2026
- Current report (foreign issuer)12 May 2026
- Current report (foreign issuer)17 Mar 2026
- Current report (foreign issuer)17 Mar 2026
- Current report (foreign issuer)13 Mar 2026
- Current report (foreign issuer)20 Jan 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-06-30 · SEC / Bioceres Crop Solutions Corp. · 10 Nov 2025
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.